{
    "Clinical Trial ID": "NCT00930930",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Cisplatin and Paclitaxel + RAD001",
        "  Cisplatin 25 mg/m2 IV weekly + RAD001 5 mg PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + RAD001 5 mg PO daily for 11 weeks",
        "  cisplatin: Given IV",
        "  everolimus: Given orally",
        "  paclitaxel: Given IV",
        "  Venous blood draw: Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment",
        "INTERVENTION 2: ",
        "  Cisplatin and Paclitaxel + Placebo",
        "  Cisplatin 25 mg/m2 IV weekly + placebo PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + placebo PO daily for 11 weeks",
        "  cisplatin: Given IV",
        "  paclitaxel: Given IV",
        "  placebo: Given orally",
        "  Venous blood draw: Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment"
    ],
    "Eligibility": [
        "Eligibility criteria",
        "  -Maximum number of patients will include two-thirds of the patients in Arm 1 and one-third of the patients for Arm 2 (total of 145 patients). Estimated time for accrual with ~ 3 patients/month would be ~ 3.5 years.",
        "Inclusion criteria:",
        "  Patients must provide informed written consent.",
        "  Patient must be  18 years of age.",
        "  ECOG performance status 0-1.",
        "  Clinical stage II or stage III triple-negative (ER and/or PR no staining or weak staining in less than or equal to 10% cells by immunohistochemistry [IHC] and HER2-negative by Herceptest [0, 1+] or FISH) invasive mammary carcinoma, confirmed by histological analysis.",
        "  Patients who have measurable* residual tumor at the primary site",
        "  *Measurable disease: any mass that can be reproducibly measured by physical examination, mammogram, and/or ultrasound and can be accurately measured in at least one dimension (longest diameter to be recorded) as 10 mm (1 cm), either in the breast or axillary lymph nodes.",
        "  Available core biopsies from the time of diagnosis. Fresh tissue must be obtainable at baseline or fresh tissue biopsy prior to treatment initiation.",
        "  Patients who will undergo surgical treatment with either segmental resection or total mastectomy.",
        "  Patients must have adequate hematologic, hepatic, and renal function. All tests must be obtained less than 4 weeks from study entry. This includes:",
        "  ANC >/=1500/mm3",
        "  Platelet count >/=100,000/mm3",
        "  Creatinine </=1.5X upper limits of normal",
        "  Bilirubin, SGOT, SGPT </=1.5X upper limits of normal*",
        "  * for patients with Gilbert\"s syndrome, direct bilirubin will be measured instead of total bilirubin.",
        "  The patient must have not had anyprior chemotherapy for primary breast cancer.",
        "  Patients with a prior history of contra-lateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer within the last 5 years.",
        "  Able to swallow and retain oral medication.",
        "  Four days prior to biopsy procedures patients must be off medications that could increase risk of bleeding (i.e. ASA, NSAIDS, Coumadin, heparin products)",
        "  Potential subjects must complete all screening assessments as outlined in the protocol.",
        "  The pre-menopausal patient of childbearing potential must have had a negative pregnancy test and agreed to use birth control methods while participating in the study. Note: Women of childbearing potential and their male counterparts should use a barrier method of contraception during and for 3 months following protocol therapy.",
        "  Ineligibility Criteria",
        "Exclusion Criteria:",
        "  Locally recurrent breast cancer.",
        "  Pregnant or lactating women.",
        "  Evidence of distant metastatic disease (i.e. lung, liver, bone, brain, etc.)",
        "  Use of CYP3A4 modifiers (Appendix A)",
        "  Serious medical illness that in the judgment of the treating physician places the patient at high risk of operative mortality.",
        "  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.",
        "  History of other malignancy. Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinomas are eligible.",
        "  History of hepatitis B or hepatitis C. If patient is judged to be at risk for having had exposure to viral B or C hepatitis (i.e. illicit IV drug use, blood transfusion prior to 1990, body piercing, tattoos, etc.), appropriate testing should be performed (i.e. Hepatitis B surface antigen antibody, and Hepatitis C antibody)",
        "  Active or uncontrolled infection requiring parenteral antibiotics.",
        "  Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.",
        "  Symptomatic neuropathy ( grade 2).",
        "  Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, or any other biologic therapy) other than the ones specified in the protocol.",
        "  Concurrent treatment with an investigational agent.",
        "  Used an investigational drug within 15 days or 5 half-lives, whichever is longer, preceding the first dose of randomized therapy."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Patients With Pathological Complete Response",
        "  Pathological complete response is defined as no residual tumor on histopathological analysis of both breast and axillary contents.",
        "  Time frame: at time of surgery, week 15-18",
        "Results 1: ",
        "  Arm/Group Title: Cisplatin and Paclitaxel + RAD001",
        "  Arm/Group Description: Cisplatin 25 mg/m2 IV weekly + RAD001 5 mg PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + RAD001 5 mg PO daily for 11 weeks",
        "  cisplatin: Given IV",
        "  everolimus: Given orally",
        "  paclitaxel: Given IV",
        "  Venous blood draw: Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment",
        "  Overall Number of Participants Analyzed: 88",
        "  Measure Type: Number",
        "  Unit of Measure: participants  34",
        "Results 2: ",
        "  Arm/Group Title: Cisplatin and Paclitaxel + Placebo",
        "  Arm/Group Description: Cisplatin 25 mg/m2 IV weekly + placebo PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + placebo PO daily for 11 weeks",
        "  cisplatin: Given IV",
        "  paclitaxel: Given IV",
        "  placebo: Given orally",
        "  Venous blood draw: Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment",
        "  Overall Number of Participants Analyzed: 44",
        "  Measure Type: Number",
        "  Unit of Measure: participants  17"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 22/96 (22.92%)",
        "  Anemia 1/96 (1.04%)",
        "  lymphopenia 1/96 (1.04%)",
        "  cardiac ischemia/infarction 1/96 (1.04%)",
        "  sinus tachycardia 2/96 (2.08%)",
        "  Dehydration 5/96 (5.21%)",
        "  colitis 1/96 (1.04%)",
        "  diarrhea 5/96 (5.21%)",
        "  ileus 1/96 (1.04%)",
        "  nausea 2/96 (2.08%)",
        "  vomiting 1/96 (1.04%)",
        "  distal small bowel obstruction 1/96 (1.04%)",
        "  edema 1/96 (1.04%)",
        "  fatigue 2/96 (2.08%)",
        "Adverse Events 2:",
        "  Total: 6/49 (12.24%)",
        "  Anemia 0/49 (0.00%)",
        "  lymphopenia 0/49 (0.00%)",
        "  cardiac ischemia/infarction 0/49 (0.00%)",
        "  sinus tachycardia 0/49 (0.00%)",
        "  Dehydration 1/49 (2.04%)",
        "  colitis 0/49 (0.00%)",
        "  diarrhea 0/49 (0.00%)",
        "  ileus 0/49 (0.00%)",
        "  nausea 1/49 (2.04%)",
        "  vomiting 1/49 (2.04%)",
        "  distal small bowel obstruction 0/49 (0.00%)",
        "  edema 0/49 (0.00%)",
        "  fatigue 0/49 (0.00%)"
    ]
}